The diagnostic AML population was identified by CD45 versus log-SSC gating with WinList (Verity Software House, Topsham, ME). The log mean fluorescence intensities of twelve cell surface antigens were calculated and incorporated into each patient's IEP along with average forward scatter (FSC) and side scatter (SSC) of the leukemic cells. Further, the coefficient of variation (CV) of CD34 was included in the IEP to assess the extent of maturation of leukemic cells. 5,9,10 Together, these independently quantified characteristics defined the IEP for each patient as a location in a 15-dimensional data space
. Summary of age and morphology and cytogenetic/molecular abnormalities associated with risk stratification at diagnosis for the phenotypic clusters determined by HCA. 
FAB Class

FAB M0
3 (1%) 0 (0%) 1 (1%) 2 (3%) 1 (2%) 0 (0%) 0 (0%) 7 (9%) 4 (21%) 3 (8%) 1 (8%) FAB M1
Unknown 48 4 14 10 7 4 2 5 4 5 3
Cytogenetic
Abnormality Normal 61 (23%) 4 (5%) 48 (47%) 11 (16%) 0 (0%) 7 (26%) 0 (0%) 11 (14%) 12 (52%) 12 (30%) 6 (38%) t(8;21) 45 (17%) 55 (72%) 1 (1%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 8 (10%) 0 (0%) 0 (0%) 0 (0%)
Inv(16)
75 (29%) 2 (3%) 7 (7%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 9 (12%) 2 (9%) 0 (0%) 0 (0%) 11q23 11 (4%) 0 (0%) 10 (10%) 46 (69%) 35 (69%) 16 (59%) 9 (82%) 12 (16%) 1 (4%) 12 (30%) 0 (0%) t(6;9) 4 (2%) 0 (0%) 4 (4%) 1 (1%) 0 (0%) 0 (0%) 0 (0%) 3 (4%) 0 (0%) 0 (0%) 0 (0%) Monosomy 7 Low 120 (46%) 57 (75%) 8 (8%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 17 (22%) 2 (9%) 0 (0%) 0 (0%) High 12 (5%) 2 (3%) 0 (0%) 0 (0%) 1 (2%) 0 (0%) 0 (0%) 6 (8%) 1 (4%) 1 (3%) 0 (0%) Supplementary Table 3 . Presence of cytogenetic or molecular abnormalities within the genotypic subclusters. 2 (2.1%) 3 (2.8%) 1 (0.7%) 4 (3.1%) 0 (0%) 14 (30.4%) 5 (9.1%) 2 (11.8%)
Risk group (cyto/mutation) Standard
A-ii (N=58)
50 (52.6%) 1 (0.9%) 0 (0%) 4 (3.1%) 0 (0%) 0 (0%) 3 (5.5%) 0 (0%)
A-iii (N=26) 0 (0%) 22 (20.2%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (1.8%) 0 (0%)
A-iv (N=32) 0 (0%) 1 (0.9%) 0 (0%) 17 (13.4%) 2 (3.4%) 5 (10.9%) 13 (23.6%) 0 (0%)
A-v (N=55)
19 (20%) 17 (15.6%) 1 (0.7%) 3 (2.4%) 1 (1.7%) 0 (0%) 3 (5.5%) 0 (0%)
A-vi (N=36) 0 (0%) 0 (0%) 6 (3.9%) 17 (13.4%) 1 (1.7%) 1 (2.2%) 6 (10.9%) 0 (0%)
B-i (N=65)
2 (2.1%) 54 (49.5%) 0 (0%) 2 (1.6%) 0 (0%) 2 (4.3%) 1 (1.8%) 1 (5.9%)
C-i (N=53)
5 (5.3%) 0 (0%) 6 (3.9%) 25 (19.7%) 5 (8.6%) 11 (23.9%) 6 (10.9%) 0 (0%) C-ii (N=42 2 (2.1%) 0 (0%) 2 (1.3%) 18 (14.2%) 18 (31%) 0 (0%) 0 (0%) 1 (5.9%)
D-i (N=68)
0 (0%) 0 (0%) 45 (29.4%) 5 (3.9%) 8 (13.8%) 0 (0%) 1 (1.8%) 0 (0%)
E-i (N=52)
0 (0%) 0 (0%) 35 (22.9%) 1 (0.8%) 1 (1.7%) 0 (0%) 0 (0%) 0 (0%)
F-i (N=28)
0 (0%) 0 (0%) 16 (10.5%) 3 (2.4%) 7 (12.1%) 0 (0%) 1 (1.8%) 0 (0%)
G-i (N=11)
0 (0%) 0 (0%) 9 (5.9%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
H-i (N=19)
0 (0%) 2 (1.8%) 10 (6.5%) 0 (0%) 0 (0%) 1 (2.2%) 1 (1.8%) 0 (0%)
K-i (N=16)
0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 10 (58.8%) * Indicates that the (%) shown is calculated with the numerator as the total of number of patients that have the genetic abnormality within a sub-cluster and the denominator as the total number of patients Supplementary 
